PMID- 24393876
OWN - NLM
STAT- MEDLINE
DCOM- 20140310
LR  - 20141120
IS  - 0385-0684 (Print)
IS  - 0385-0684 (Linking)
VI  - 40
IP  - 12
DP  - 2013 Nov
TI  - [Clinical significance of the human epidermal growth factor receptor 2( HER2) in 
      patients with recurrent gastric cancer who received S-1 adjuvant chemotherapy].
PG  - 1647-9
AB  - PURPOSE: The aim of this study was to clarify the human epidermal growth factor 
      receptor 2( HER2) positivity, clinicopathological characteristics, and survival 
      of patients with recurrent HER2-positive gastric cancer who received S-1 adjuvant 
      chemotherapy. METHODS: Thirty-eight patients with recurrent gastric cancer who 
      underwent curative D2 surgery and received S-1 adjuvant chemotherapy between June 
      2002 and December 2011 were examined. HER2 positivity was determined as defined 
      in the ToGA study. RESULTS: The positivity score was assessed by 
      immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) as 
      follows: IHC 0 in 27 patients, IHC 1+in 4, IHC 2+/FISH-in 3, IHC 2+/FISH+in 1, 
      and IHC 3+in 3. The HER2 positivity rate was 10.5% (4/38). HER2-positive 
      recurrent gastric cancer was characterized by a differentiated histological 
      feature and frequent blood vessel invasion. However, the recurrence and survival 
      rates were not significantly different between the HER2-negative and 
      HER2-positive tumors. CONCLUSIONS: The HER2 positivity rate after S-1 adjuvant 
      chemotherapy did not differ significantly between patients with recurrent gastric 
      cancer and those with primary Stage II/III gastric cancer, suggesting that S-1 
      adjuvant chemotherapy was equally effective, regardless of HER2 status.
FAU - Aoyama, Toru
AU  - Aoyama T
AD  - Dept. of Gastrointestinal Surgery, Kanagawa Cancer Center.
FAU - Hayashi, Tsutomu
AU  - Hayashi T
FAU - Fujikawa, Hirohito
AU  - Fujikawa H
FAU - Ogata, Takashi
AU  - Ogata T
FAU - Cho, Haruhiko
AU  - Cho H
FAU - Wada, Hiroo
AU  - Wada H
FAU - Kitani, Yuichi
AU  - Kitani Y
FAU - Yukawa, Norio
AU  - Yukawa N
FAU - Oshima, Takashi
AU  - Oshima T
FAU - Rino, Yasushi
AU  - Rino Y
FAU - Ozawa, Yukihiro
AU  - Ozawa Y
FAU - Masuda, Munetaka
AU  - Masuda M
FAU - Yoshikawa, Takaki
AU  - Yoshikawa T
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Gan To Kagaku Ryoho
JT  - Gan to kagaku ryoho. Cancer & chemotherapy
JID - 7810034
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - 0 (Drug Combinations)
RN  - 150863-82-4 (S 1 (combination))
RN  - 1548R74NSZ (Tegafur)
RN  - 5VT6420TIG (Oxonic Acid)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antimetabolites, Antineoplastic/*therapeutic use
MH  - Chemotherapy, Adjuvant
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Oxonic Acid/*therapeutic use
MH  - Receptor, ErbB-2/*analysis
MH  - Recurrence
MH  - Stomach Neoplasms/chemistry/*drug therapy/pathology/surgery
MH  - Tegafur/*therapeutic use
EDAT- 2014/01/08 06:00
MHDA- 2014/03/13 06:00
CRDT- 2014/01/08 06:00
PHST- 2014/01/08 06:00 [entrez]
PHST- 2014/01/08 06:00 [pubmed]
PHST- 2014/03/13 06:00 [medline]
PST - ppublish
SO  - Gan To Kagaku Ryoho. 2013 Nov;40(12):1647-9.